EXPLORING HOW SAP HELPS IN MANAGING CLINICAL TRIALS, RESEARCH DATA, AND COLLABORATION IN THE PHARMACEUTICAL INDUSTRY
Keywords:
SAP, Pharmaceutical Research, Clinical Trials Data Management, Analytics, Collaboration, Regulatory Compliance, Resource Planning, Supply Chain Management, Pharmacovigilance, Safety Monitoring, Innovation Scalability, Clinical Trial Management Systems (CTMS), Research and Development (R&D)Abstract
This paper aims at discussing the integration of SAP and their functions within the planning, management, and monitoring of clinical trials. Clinical Trial Management Systems (CTMS) have become an integral component of the SAP programs in the pharmaceutical unit for the proper management and executive control over clinical trials. As a result of SAP’s comprehensive data management and analytical functionalities, it allows organisations to gain better insights into the trials’ status, identify more efficient ways to allocate resources as well as apply strict regulatory compliance. More so, the following abstract focuses on the evolution of communication with SAP platforms towards strengthening multi-disciplinary collaboration in drug development. With the help of integration tools, including project management and sharing systems, in the SAP, it is possible to reach the effective collaboration of research teams regardless of the department or location [1]. This encourages innovation, quickens the decision-making approach, and ends in the promulgation of the quality and effectiveness of pharmaceutical R&D programs. One possible way is to rely on clinical trials management software that relies on the architecture of ‘SAP’ as the underlying scientific principles inherent to any research project, including clinical research, demand detailed planning. In the case study, the proposed LTPD system software is implemented using SAP, which comes up with significant advantages. A clinical research file, comprises usually a richly structured study protocol that is designed to control all aspects of a study, comprising all relevant phases of study design, execution, and finalization of the study. The study protocol generates tests and related results in case of controlled tests which are necessary for technique development in capability management such as quality or deviation management or in project management that leads to project handbook. In general, the generated data and all subsequent data are locked up and stored in the respective data storage areas where they are stored in a restricted and unauthorized manner such that the relevant CDA and the ST may determine all the required functionalities and operations for optimally performing a study protocol. Only the relevant organizational roles can utilize such available data or functionalities if permission and roles for utilization from the relevant roles are available. This leads finally to the takeout of the final data report after evaluating scientifically all available and relevant study protocol data [1]. To maintain innovation, the pharmaceutical industry needs to invest big. Pharmaceutical industry faces vast hindrance in inventive drug discovery and development, in the case of large failure rate of perceived 90% drug candidates in clinical trials. The development of new and innovative bio-informatics software such as Artificial Intelligence (AI), Language Learning Models (LLM) technologies, Clinical Trials Management System (CTMS) can aid the industry to manage these threats and the in-silico drug discovery and development may turn cost effective. The main task of Drug discovery including target identification, target validation and lead generating were the affected segments. Data management and warehousing platform which stores, standardizes, and aggregates data through various business process management and workflow management tools. The production of correct clinical development and drug discovery data means correct and efficient decision-making and avoiding probable regulatory and health issues. Therefore, throughout the R&D process, data management plays a crucial role. It is therefore essential to come up with a robust data management system [2].
Downloads
References
M. Thor, J. H. Oh, A. P. Apte, and J. O. Deasy, “Registering Study Analysis Plans (SAPs) Before Dissecting Your Data—Updating and Standardizing Outcome Modeling,” Frontiers in Oncology, vol. 10, Jun. 2020, doi: https://doi.org/10.3389/fonc.2020.00978
C. De Angelis et al., “Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors,” New England Journal of Medicine, vol. 351, no. 12, pp. 1250–1251, Sep. 2004, doi: https://doi.org/10.1056/nejme048225
D. Moher, “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement,” Annals of Internal Medicine, vol. 151, no. 4, p. 264, Aug. 2009.
C. Laine et al., “Clinical trial registration: looking back and moving ahead,” vol. 369, no. 9577, pp. 1909–1911, Jun. 2007, doi: https://doi.org/10.1016/s0140-6736(07)60894-0
J. C. Macdonald, D. C. Isom, D. D. Evans, and K. J. Page, “Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?,” Frontiers in Medicine, vol. 8, May 2021, doi: https://doi.o rg/10.3 389/f med.2021.660808
L. X. Yu, “Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control,” Pharmaceutical Research, vol. 25, no. 4, pp. 781–791, Jan. 2008, doi: https://doi.org/10 .1007/ s11 095-007-9511-1
J. W. Scannell, A. Blanckley, H. Boldon, and B. Warrington, “Diagnosing the decline in pharmaceutical R&D efficiency,” Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 191–200, Mar. 2012, doi: https://doi.org/10.1038/nrd3681. Available: http://www.nature.com/articles/nrd3681
J. Vamathevan et al., “Applications of machine learning in drug discovery and development,” Nature Reviews Drug Discovery, vol. 18, no. 6, pp. 463–477, Apr. 2019, doi: https://doi.org/10.1038/s41573-019-0024-5. Available: https://www.nature.com/articles/s41573-019-0024-5
M. Bramlet, L. Olivieri, K. Farooqi, B. Ripley, and M. Coakley, “Impact of Three-Dimensional Printing on the Study and Treatment of Congenital Heart Disease,” Circulation Research, vol. 120, no. 6, pp. 904–907, Mar. 2017, doi: https://doi.org/10.1161/circresaha.116.310546
S. K. Gill, A. F. Christopher, V. Gupta, and P. Bansal, “Emerging role of bioinformatics tools and software in evolution of clinical research,” Perspectives in Clinical Research, vol. 7, no. 3, pp. 115–122, 2016, doi: https://doi.org/10.4103/2229-3485.184782. Available: https://ww w.ncbi.nlm.n ih.gov/pmc/ articles/PMC4936069/
D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists,” Nucleic Acids Research, vol. 37, no. 1, pp. 1–13, Nov. 2008, doi: https://doi.org/10.1093/nar/gkn923
X. Chen, J.-D. Qiu, S.-P. Shi, S.-B. Suo, S.-Y. Huang, and R.-P. Liang, “Incorporating key position and amino acid residue features to identify general and species-specific Ubiquitin conjugation sites,” Bioinformatics, vol. 29, no. 13, pp. 1614–1622, Apr. 2013, doi: https://doi.org/10. 109 3/bioi nform atics/ btt196. Available: https://academic.oup.com/bioinformatics/article/29/13/1614/185116?login=true
M. A. Farnum et al., “A dimensional warehouse for integrating operational data from clinical trials,” Database, vol. 2019, Jan. 2019, doi: https://doi.org/10.1093/database/baz039
Z. Chen, X. Liu, W. Hogan, E. Shenkman, and J. Bian, “Applications of artificial intelligence in drug development using real-world data,” Drug Discovery Today, vol. 26, no. 5, pp. 1256–1264, May 2021, doi: https://doi.org/10.1016/j.drudis.2020.12.013. Available: https://arxiv.org/ftp/a rxiv/paper s/2101 /21 01.08904.pdf.
M. J. Lamberti et al., “A Study on the Application and Use of Artificial Intelligence to Support Drug Development,” Clinical Therapeutics, vol. 41, no. 8, pp. 1414–1426, Aug. 2019, doi: https:// doi.org/10 .1016/j.clinthera.2019.05.018.
J. Jiménez-Luna, F. Grisoni, and G. Schneider, “Drug discovery with explainable artificial intelligence,” Nature Machine Intelligence, vol. 2, no. 10, pp. 573–584, Oct. 2020, doi: https://doi.org/10.1038/s42256-020-00236-4.
M. Lee, H. Ly, C. C. Möller, and M. Ringel, “Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation,” Clinical Pharmacology & Therapeutics, vol. 105, no. 4, pp. 886–898, Apr. 2019, doi: https://doi.org/10.1002/cpt.1354.
M. P. Hekkert, R. A. A. Suurs, S. O. Negro, S. Kuhlmann, and R. E. H. M. Smits, “Functions of innovation systems: A new approach for analysing technological change,” Technological Forecasting and Social Change, vol. 74, no. 4, pp. 413–432, May 2007, doi: https://do i.org/1 0.1016/j.t echfor e.20 06.03.002
M. Pfister and D. Z. D’Argenio, “The Emerging Scientific Discipline of Pharmacometrics,” The Journal of Clinical Pharmacology, vol. 50, no. S9, pp. 6S6S, Sep. 2010, doi: https://do i.org/10.1 177/0091 2700 10377789.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 IEJRD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
